Additional dexamethasone improves the response rate among patients with multiple myeloma treated with single agent bortezomib
- PMID: 16818270
Additional dexamethasone improves the response rate among patients with multiple myeloma treated with single agent bortezomib
Comment on
-
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.Haematologica. 2006 Jul;91(7):929-34. Haematologica. 2006. PMID: 16818280 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical